Clinical trial • Phase III • Oncology
AZD0120 for Relapsed or refractory multiple myeloma
Phase III trial of AZD0120 for Relapsed or refractory multiple myeloma.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Relapsed or refractory multiple myeloma
- Trial Stage
- Phase III
- Drug Modality
- Cell therapy|Monoclonal antibody|Small molecule
- Orphan Drug
- Yes
Key dates
- Initial CTIS Submission Date
- 18-12-2025
- First CTIS Authorization Date
- 30-04-2026
Trial design
Randomised, open-label, standard therapy regimens (dkd, dpd, pvd, or kd) as determined by investigator. comparator products listed in the dossier: darzalex (daratumumab) 1800 mg solution for injection; kyprolis (carfilzomib) powder for solution for infusion (10 mg, 30 mg, 60 mg presentations); pomalidomide zentiva (1 mg, 2 mg, 3 mg, 4 mg hard capsules); bortezomib hikma 3.5 mg powder for injection; dexamethason (0.5 mg, 1.5 mg, 4 mg, 8 mg tablets). dose schedules not specified in the ctis metadata.-controlled Phase III trial in France, Germany, Italy and others.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Standard therapy regimens (DKd, DPd, PVd, or Kd) as determined by Investigator. Comparator products listed in the dossier: DARZALEX (daratumumab) 1800 mg solution for injection; Kyprolis (carfilzomib) powder for solution for infusion (10 mg, 30 mg, 60 mg presentations); Pomalidomide Zentiva (1 mg, 2 mg, 3 mg, 4 mg hard capsules); Bortezomib Hikma 3.5 mg powder for injection; Dexamethason (0.5 mg, 1.5 mg, 4 mg, 8 mg tablets). Dose schedules not specified in the CTIS metadata.
- Target Sample Size
- 355
Eligibility
Recruits 355 Participants must be 18 years or older; vulnerable population not selected (isVulnerablePopulationSelected=false). Informed consent is required from the adult participant. Country-specific subject information and informed consent forms (adult ICFs, pregnant partner ICF, optional genomics ICFs) were provided in the application documents; no paediatric assent procedures are specified..
- Vulnerable Population
- Participants must be 18 years or older; vulnerable population not selected (isVulnerablePopulationSelected=false). Informed consent is required from the adult participant. Country-specific subject information and informed consent forms (adult ICFs, pregnant partner ICF, optional genomics ICFs) were provided in the application documents; no paediatric assent procedures are specified.
Inclusion criteria
- {"criterion_text":"- Arm A and B: Participants must be 18 years or older, at the time of signing the ICF."}
- {"criterion_text":"- Arm A and B: Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria."}
- {"criterion_text":"- Arm A and B: Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c) Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda FLC ratio."}
- {"criterion_text":"- Arm A and B: Participant must have documented evidence of PD by IMWG 2016 criteria based on Investigator’s determination during or after the most recent line of therapy. Participants who have had only 1 prior line of therapy must have disease that has progressed within 47 months of a stem cell transplant, or if not transplanted, then within 42 months of starting initial therapy."}
- {"criterion_text":"- Arm A and B: Participant must have received 1 to 3 lines of prior therapy including an IMiD and either a PI or an anti-CD38 antibody. Participant must have undergone at least 2 complete cycles of treatment for each line of therapy, unless PD was the best response to the line of therapy."}
- {"criterion_text":"- Arm A and B: Participant is eligible to receive at least one of the standard regimens (DKd, PVd, DPd, or Kd) as determined by the Investigator."}
- {"criterion_text":"- Arm A and B: Participants must have an ECOG performance status score of 0 to 1."}
- {"criterion_text":"- Arm A and B: Adequate organ and bone marrow function."}
Exclusion criteria
- {"criterion_text":"- Arm A and B: Participant has active or prior CNS or meningeal involvement of MM."}
- {"criterion_text":"- Arm A and B: Participant has primary amyloidosis, active plasma cell leukemia (≥5% circulating plasma cells), Waldenström macroglobulinemia, or POEMS syndrome."}
- {"criterion_text":"- Arm A and B: Participant has primary refractory MM (no minimal response to any prior therapy)."}
- {"criterion_text":"- Arm A and B: Participant has significant neurological or psychiatric condition posing risk or impairing evaluation (e.g., severe brain injury, dementia, Parkinson’s, stroke, intracranial hemorrhage, or seizure within 6 months). Stable mild conditions may be eligible at Investigator discretion."}
- {"criterion_text":"- Arm A and B: Participant has any other significant medical condition that increases unacceptable risk, interferes with therapy delivery, or confounds evaluation, including: -Serious active or uncontrolled infection, -Requirement of supplemental oxygen, -Active autoimmune disease or history within 2 years, -Clinically significant gastrointestinal disease (including IBD requiring treatment within 5 years)."}
- {"criterion_text":"- Arm A and B: Participant previously received any BCMA-targeted treatment."}
- {"criterion_text":"- Arm A and B: Participant previously received CAR-T or CAR-NK therapy."}
- {"criterion_text":"- Arm A and B: Participant previously received T-cell engager therapy."}
- {"criterion_text":"- Arm A and B: Participant previously received allogeneic stem cell transplant at any time or ASCT within 12 weeks before randomization."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Arm A and B: PFS: defined as the time from the randomisation until the date of documented disease progression according to IMWG 2016 criteria as assessed by BICR or death due to any cause, whichever occurs first.","definition_or_measurement_approach":"Time from randomisation to documented disease progression per IMWG 2016 criteria as assessed by blinded independent central review (BICR) or death from any cause; whichever occurs first."}
- {"endpoint_text":"- Arm A and B: MRD negative CR rate at 9 months: defined as the proportion of participants with MRD negative status and have a response of CR or sCR (according to the IMWG2016 criteria) at 9 months (± 3 months) from randomisation before initiation of subsequent anti-myeloma therapy.","definition_or_measurement_approach":"Proportion of participants who are MRD negative and have CR or sCR per IMWG 2016 at 9 months (±3 months) from randomisation, prior to start of subsequent anti-myeloma therapy."}
Secondary endpoints
- {"endpoint_text":"- Arm A and B: OS: defined as time from randomisation until date of death due to any cause","definition_or_measurement_approach":"Time from randomisation to death from any cause."}
- {"endpoint_text":"- Arm A and B: CRR (CR/sCR rate): defined as the proportion of participants who achieved a best response of CR or better according to IMWG 2016 criteria, as assessed by BICR.","definition_or_measurement_approach":"Proportion achieving best response of CR or sCR per IMWG 2016 assessed by BICR."}
- {"endpoint_text":"- Arm A and B: ORR: defined as the proportion of participants who achieved PR or better according to IMWG 2016 criteria, as assessed by BICR.","definition_or_measurement_approach":"Proportion achieving PR or better per IMWG 2016 assessed by BICR."}
- {"endpoint_text":"- Arm A and B: DoR: defined as the time from first documented confirmed response until date of documented PD per IMWG2016 criteria or death due to any cause, whichever occurs first.","definition_or_measurement_approach":"Time from first documented confirmed response to documented progression per IMWG 2016 or death, whichever occurs first."}
- {"endpoint_text":"- Arm A and B: TTR: defined as the time from randomisation until the date of first documented objective response, as assessed per IMWG 2016 criteria.","definition_or_measurement_approach":"Time from randomisation to first documented objective response per IMWG 2016."}
- {"endpoint_text":"- Arm A and B: MRD negative CR rate: defined as the proportion of participants who have MRD negative status and have a response of CR or sCR (according to the IMWG 2016 criteria) at any time after the date of randomisation and before initiation of subsequent therapy.","definition_or_measurement_approach":"Proportion with MRD negative status and CR or sCR at any time after randomisation and before subsequent therapy, per IMWG 2016."}
- {"endpoint_text":"- Arm A and B: Rate of sustained MRD negative CR: defined as the proportion of participants who have achieved MRD negative status and have a response of CR or sCR, confirmed minimum 1 year apart without any examination showing MRD positive status in between status assessments.","definition_or_measurement_approach":"Proportion achieving MRD negative CR or sCR confirmed at least 1 year apart with no interim MRD positive assessments."}
- {"endpoint_text":"- Arm A and B: PFS-2: defined as the time from randomisation to progression on next line of therapy, as assessed by Investigator or death due to any cause.","definition_or_measurement_approach":"Time from randomisation to progression on next line of therapy per investigator assessment or death from any cause."}
- {"endpoint_text":"- Arm A and B: TFI: defined as the time from last dose of study intervention to the date of the first dose of subsequent anti-myeloma therapy.","definition_or_measurement_approach":"Time from last study intervention dose to first dose of subsequent anti-myeloma therapy."}
- {"endpoint_text":"- Arm A and B: Safety will be evaluated in terms of AEs, vital signs, and clinical laboratory results.","definition_or_measurement_approach":"Safety assessed by adverse events, vital signs, and clinical laboratory results."}
Other endpoints
- {"endpoint_text":"- immunogenicity, patient-reported outcomes, biomarkers of response&resistance,health care utilization","definition_or_measurement_approach":"Exploratory assessments including immunogenicity, patient-reported outcomes, biomarkers of response and resistance, and health-care utilisation (as listed in trial scope/secondary objectives)."}
Recruitment
- Planned Sample Size
- 355
- Recruitment Window Months
- 50
- Consent Approach
- Informed consent is required from participants (participants must be 18 years or older). Subject information and informed consent form documents were submitted (country-specific adult ICFs, pregnant partner ICFs, optional genomics ICFs). Consent is provided by the adult participant; no paediatric assent procedures are specified in the application metadata.
Geography
- Total Number Of Sites
- 37
- Total Number Of Participants
- 153
France
- Earliest CTIS Part Ii Submission Date
- 25-02-2026
- Latest Decision Or Authorization Date
- 04-05-2026
- Processing Time Days
- 68
- Number Of Sites
- 6
- Number Of Participants
- 17
Sites
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Clinical Hematology
- Principal Investigator Name
- Cyrille Touzeau
- Principal Investigator Email
- cyrille.touzeau@chu-nantes.fr
- Contact Person Name
- Cyrille Touzeau
- Contact Person Email
- cyrille.touzeau@chu-nantes.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Service des maladies du sang
- Principal Investigator Name
- Salomon Manier
- Principal Investigator Email
- salomon.manier@chru-lille.fr
- Contact Person Name
- Salomon Manier
- Contact Person Email
- salomon.manier@chru-lille.fr
- Site Name
- Centre Hospitalier Universitaire De Toulouse
- Department Name
- Hematology
- Principal Investigator Name
- Aurore Perrot
- Principal Investigator Email
- perrot.aurore@iuct-oncopole.fr
- Contact Person Name
- Aurore Perrot
- Contact Person Email
- perrot.aurore@iuct-oncopole.fr
- Site Name
- Centre Hospitalier Universitaire De Poitiers
- Department Name
- Pôle régional de cancérologie
- Principal Investigator Name
- Xavier Leleu
- Principal Investigator Email
- xavier.leleu@chu-poitiers.fr
- Contact Person Name
- Xavier Leleu
- Contact Person Email
- xavier.leleu@chu-poitiers.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Hematology
- Principal Investigator Name
- Lionel Karlin
- Principal Investigator Email
- lionel.karlin@chu-lyon.fr
- Contact Person Name
- Lionel Karlin
- Contact Person Email
- lionel.karlin@chu-lyon.fr
- Site Name
- Hopital Saint Louis
- Department Name
- Immunology - Hematology
- Principal Investigator Name
- Bertrand Arnulf
- Principal Investigator Email
- bertrand.arnulf@sls.aphp.fr
- Contact Person Name
- Bertrand Arnulf
- Contact Person Email
- bertrand.arnulf@sls.aphp.fr
Germany
- Earliest CTIS Part Ii Submission Date
- 13-04-2026
- Latest Decision Or Authorization Date
- 04-05-2026
- Processing Time Days
- 21
- Number Of Sites
- 9
- Number Of Participants
- 29
Sites
- Site Name
- Universitaet Leipzig
- Department Name
- Klinik u. Poliklinik f. Hämatologie, Zelltherapie, Hämostaseologie u. Infektiologie
- Principal Investigator Name
- Vladan Vucinic
- Principal Investigator Email
- Vladan.Vucinic@medizin.uni-leipzig.de
- Contact Person Name
- Vladan Vucinic
- Contact Person Email
- Vladan.Vucinic@medizin.uni-leipzig.de
- Site Name
- Technische Universitaet Dresden
- Department Name
- Med. Klinik und Poliklinik I
- Principal Investigator Name
- Raphael Teipel
- Principal Investigator Email
- raphael.teipel@ukdd.de
- Contact Person Name
- Raphael Teipel
- Contact Person Email
- raphael.teipel@ukdd.de
- Site Name
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
- Department Name
- III. Med. Klinik u. Poliklinik Hämatologie u. Med. Onkologie
- Principal Investigator Name
- Eva-Maria Wagner-Drouet
- Principal Investigator Email
- eva.wagner@unimedizin-mainz.de
- Contact Person Name
- Eva-Maria Wagner-Drouet
- Contact Person Email
- eva.wagner@unimedizin-mainz.de
- Site Name
- Universitaetsklinikum Erlangen AöR
- Department Name
- Medizinische Klinik 5 – Hämatologie und Internistische Onkologie
- Principal Investigator Name
- Barbara Ferstl
- Principal Investigator Email
- barbara.ferstl@uk-erlangen.de
- Contact Person Name
- Barbara Ferstl
- Contact Person Email
- barbara.ferstl@uk-erlangen.de
- Site Name
- Medical Center - University Of Freiburg
- Department Name
- Klinik f. Innere Medizin I Hämatologie, Onkologie u. Stammzellentransplantation
- Principal Investigator Name
- Ralph Wäsch
- Principal Investigator Email
- ralph.waesch@uniklinik-freiburg.de
- Contact Person Name
- Ralph Wäsch
- Contact Person Email
- ralph.waesch@uniklinik-freiburg.de
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- Klinik f. Hämatologie u. Stammzellentransplantation
- Principal Investigator Name
- Bastian von Treschkow
- Principal Investigator Email
- bastian.vontresckow@uk-essen.de
- Contact Person Name
- Bastian von Treschkow
- Contact Person Email
- bastian.vontresckow@uk-essen.de
- Site Name
- Universitaetsklinikum Wuerzburg AöR
- Department Name
- Med. Klinik und Poliklinik II
- Principal Investigator Name
- Martin Kortüm
- Principal Investigator Email
- kortuem_m@ukw.de
- Contact Person Name
- Martin Kortüm
- Contact Person Email
- kortuem_m@ukw.de
- Site Name
- Klinikum Nuernberg
- Department Name
- Universitätsklinik f. Innere Medizin 5 – Onkologie und Hämatologie
- Principal Investigator Name
- Stefan Knop
- Principal Investigator Email
- stefan.knop@klinikum-nuernberg.de
- Contact Person Name
- Stefan Knop
- Contact Person Email
- stefan.knop@klinikum-nuernberg.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CBF)
- Principal Investigator Name
- Stephan Bohl
- Principal Investigator Email
- stephan.bohl@charite.de
- Contact Person Name
- Stephan Bohl
- Contact Person Email
- stephan.bohl@charite.de
- Site Name
- University Medical Center Hamburg-Eppendorf
- Department Name
- Zentrum für Onkologie, II. Medizinischen Klinik und Poliklinik
- Principal Investigator Name
- Katja Weisel
- Principal Investigator Email
- k.weisel@uke.de
- Contact Person Name
- Katja Weisel
- Contact Person Email
- k.weisel@uke.de
Italy
- Earliest CTIS Part Ii Submission Date
- 31-03-2026
- Latest Decision Or Authorization Date
- 04-05-2026
- Processing Time Days
- 34
- Number Of Sites
- 6
- Number Of Participants
- 25
Sites
- Site Name
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Department Name
- Dipartimento di Oncologia ed Emato-Oncologia
- Principal Investigator Name
- Paolo Corradini
- Principal Investigator Email
- paolo.corradini@unimi.it
- Contact Person Name
- Paolo Corradini
- Contact Person Email
- paolo.corradini@unimi.it
- Site Name
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Department Name
- SC Ematologia Oncologica e Trapianto di Cellule Staminali
- Principal Investigator Name
- Antonio Pinto
- Principal Investigator Email
- a.pinto@istitutotumori.na.it
- Contact Person Name
- Antonio Pinto
- Contact Person Email
- a.pinto@istitutotumori.na.it
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- Dipartimento Malattie Oncologiche ed Ematologiche
- Principal Investigator Name
- Elena Zamagni
- Principal Investigator Email
- e.zamagni@unibo.it
- Contact Person Name
- Elena Zamagni
- Contact Person Email
- e.zamagni@unibo.it
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- U. O. di Ematologia e Trapianto Midollo Osseo (UTMO)
- Principal Investigator Name
- Fabio Ciceri
- Principal Investigator Email
- ciceri.clinicaltrials@hsr.it
- Contact Person Name
- Fabio Ciceri
- Contact Person Email
- ciceri.clinicaltrials@hsr.it
- Site Name
- Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
- Department Name
- Hematology U Division/Department of "Biotecnologie Molecolari e Scienze per la Salute"
- Principal Investigator Name
- Francesca Gay
- Principal Investigator Email
- francesca.gay@unito.it
- Contact Person Name
- Francesca Gay
- Contact Person Email
- francesca.gay@unito.it
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- U.O. Oncologia Medica ed Ematologia
- Principal Investigator Name
- Armando Santoro
- Principal Investigator Email
- armando.santoro@cancercenter.humanitas.it
- Contact Person Name
- Armando Santoro
- Contact Person Email
- armando.santoro@cancercenter.humanitas.it
Spain
- Earliest CTIS Part Ii Submission Date
- 26-03-2026
- Latest Decision Or Authorization Date
- 04-05-2026
- Processing Time Days
- 39
- Number Of Sites
- 8
- Number Of Participants
- 44
Sites
- Site Name
- Hospital Universitario De Salamanca
- Department Name
- Hematology
- Principal Investigator Name
- Maria Victoria Mateos
- Principal Investigator Email
- mvmateos@usal.es
- Contact Person Name
- Maria Victoria Mateos
- Contact Person Email
- mvmateos@usal.es
- Site Name
- Clinica Universidad De Navarra (Pamplona)
- Department Name
- Hematology
- Principal Investigator Name
- Paula Rodriguez Otero
- Principal Investigator Email
- paurodriguez@unav.es
- Contact Person Name
- Paula Rodriguez Otero
- Contact Person Email
- paurodriguez@unav.es
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Hematology
- Principal Investigator Name
- Javier de la Rubia Comos
- Principal Investigator Email
- delarubia_jav@gva.es
- Contact Person Name
- Javier de la Rubia Comos
- Contact Person Email
- delarubia_jav@gva.es
- Site Name
- Clinica Universidad De Navarra (Madrid)
- Department Name
- Hematology
- Principal Investigator Name
- Paula Rodriguez Otero
- Principal Investigator Email
- paurodriguez@unav.es
- Contact Person Name
- Paula Rodriguez Otero
- Contact Person Email
- paurodriguez@unav.es
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Hematology
- Principal Investigator Name
- Joaquin Martinez Lopez
- Principal Investigator Email
- jmarti01@med.ucm.es
- Contact Person Name
- Joaquin Martinez Lopez
- Contact Person Email
- jmarti01@med.ucm.es
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Hematology
- Principal Investigator Name
- Carlos Fernandez de Larrea
- Principal Investigator Email
- CFERNAN1@clinic.cat
- Contact Person Name
- Carlos Fernandez de Larrea
- Contact Person Email
- CFERNAN1@clinic.cat
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Hematology
- Principal Investigator Name
- Enrique Ocio San Miguel
- Principal Investigator Email
- ocioem@unican.es
- Contact Person Name
- Enrique Ocio San Miguel
- Contact Person Email
- ocioem@unican.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Hematology
- Principal Investigator Name
- Mercedes Gironella Mesa
- Principal Investigator Email
- mgironella@vhio.net
- Contact Person Name
- Mercedes Gironella Mesa
- Contact Person Email
- mgironella@vhio.net
Norway
- Earliest CTIS Part Ii Submission Date
- 17-04-2026
- Latest Decision Or Authorization Date
- 30-04-2026
- Processing Time Days
- 13
- Number Of Sites
- 1
- Number Of Participants
- 9
Sites
- Site Name
- Oslo Universitetssykehus HF
- Department Name
- Department of Hematology
- Principal Investigator Name
- Ingerid Abrahamsen
- Principal Investigator Email
- inabra@ous-hf.no
- Contact Person Name
- Ingerid Abrahamsen
- Contact Person Email
- inabra@ous-hf.no
Poland
- Earliest CTIS Part Ii Submission Date
- 14-04-2026
- Latest Decision Or Authorization Date
- 30-04-2026
- Processing Time Days
- 16
- Number Of Sites
- 7
- Number Of Participants
- 29
Sites
- Site Name
- Instytut Hematologii I Transfuzjologii
- Department Name
- Klinika Hematologii
- Principal Investigator Name
- Ewa Lech-Maranda
- Principal Investigator Email
- emaranda@ihit.waw.pl
- Contact Person Name
- Ewa Lech-Maranda
- Contact Person Email
- emaranda@ihit.waw.pl
- Site Name
- Uniwersytecki Szpital Kliniczny W Poznaniu
- Department Name
- Oddzial Hematologii i Transplantacji Szpiku
- Principal Investigator Name
- Dominik Dytfeld
- Principal Investigator Email
- dytfeld@me.com
- Contact Person Name
- Dominik Dytfeld
- Contact Person Email
- dytfeld@me.com
- Site Name
- Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
- Department Name
- Klinika Hematologii, Terapii Komorkowych i Chorob Wewnetrznych
- Principal Investigator Name
- Tomasz Wrobel
- Principal Investigator Email
- tomasz.wrobel@umed.wroc.pl
- Contact Person Name
- Tomasz Wrobel
- Contact Person Email
- tomasz.wrobel@umed.wroc.pl
- Site Name
- Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
- Department Name
- Klinika Transplantacji Szpiku i Onkohematologii
- Principal Investigator Name
- Sebastian Giebel
- Principal Investigator Email
- sebastian.giebel@gliwice.nio.gov.pl
- Contact Person Name
- Sebastian Giebel
- Contact Person Email
- sebastian.giebel@gliwice.nio.gov.pl
- Site Name
- Uniwersyteckie Centrum Kliniczne
- Department Name
- Klinika Hematologii i Transplantologii
- Principal Investigator Name
- Jan Zaucha
- Principal Investigator Email
- hematologia@uck.gda.pl
- Contact Person Name
- Jan Zaucha
- Contact Person Email
- hematologia@uck.gda.pl
- Site Name
- Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
- Department Name
- Oddzial Hematologii i Transplantacji Szpiku
- Principal Investigator Name
- Wojciech Legiec
- Principal Investigator Email
- legiec.wojciech@gmail.com
- Contact Person Name
- Wojciech Legiec
- Contact Person Email
- legiec.wojciech@gmail.com
- Site Name
- Uniwersyteckie Centrum Kliniczne (additional site entry)
Sponsor
Primary sponsor
- Full Name
- AstraZeneca AB
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- AZD0120
- Active Substance
- AZD0120
- Modality
- Cell therapy
- Routes Of Administration
- Intravenous use
- Route
- Intravenous
- Authorisation Status
- prodAuthStatus 1 (as recorded in product dictionary)
Related trials
Other published trials that may interest you.